193902-87-3

Basic information

• Product Name: 4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 4-(4-AMINO-2-(TRIFLUOROMETHYL)PHENYL)PIPERAZINE-1-CARBOXYLATE;4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(4-Boc-piperazin-1-yl)-3-trifluoromethylaniline;1-Boc-4-(4-amino-2-trifluoromethylphenyl)piperazine;4-(4-Bocpieperazin-1-yl)-3-trifluoroMethylaniline
• CAS NO: 193902-87-3
• Molecular Formula: C16H22F3N3O2
• Molecular Weight: 345.36
• EINECS: 200-258-5
• Product Categories: pharmacetical
• Mol File: 193902-87-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 446.521 °C at 760 mmHg
• Flash Point: 223.848 °C
• Appearance: /
• Density: 1.252±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.46±0.10(Predicted)
• CAS DataBase Reference: 4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(193902-87-3)
• EPA Substance Registry System: 4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(193902-87-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 193902-87-3(Hazardous Substances Data)

Usage

General Description

4-(4-Amino-2-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C18H24N4O2F3. It is a tert-butyl ester derivative of piperazine-1-carboxylic acid, and it contains an amino group and a trifluoromethyl-phenyl group. 4-(4-AMINO-2-TRIFLUOROMETHYL-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is commonly used in pharmaceutical research and drug development as a building block for the synthesis of various heterocyclic compounds and potential drug candidates. It may also have applications in the fields of organic chemistry and medicinal chemistry due to its unique chemical structure and potential pharmacological activities.

InChI:InChI=1/C16H22F3N3O2/c1-15(2,3)24-14(23)22-8-6-21(7-9-22)13-5-4-11(20)10-12(13)16(17,18)19/h4-5,10H,6-9,20H2,1-3H3

Upstream product

• 193902-86-2 tert-butyl 4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate 
• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 

Downstream Products

• 1222999-58-7 9-(6-aminopyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one 

Relevant articles and documents

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES

Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1~X5, R1~R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.

IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS

The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.